Incyte announces positive phase III REACH3 study data published in NEJM for ruxolitinib in chronic graft-versus-host disease
Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.
